New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
August 14, 2017 – Natco Pharma announced the approval of its AB-rated generic to Shire’s Fosrenol (lanthanum carbonate) chewable tablets, to reduce serum phosphate in patients with end stage renal disease.
Download PDF
Return to publications
